Abstract 427P
Background
Several important factors affect directly or indirectly the quality of life of women with cancer in India. Several unmet needs were found to be unaddressed. This program aims to empower the patient, improve quality of life and encourage them to actively participate in the healing process. Hospitals and oncologists are challenged to develop programs that support the growing number of cancer patients. Failure to address leads to decreased compliance and outcomes.
Methods
Patients will be enrolled to participate in the introductory half a day program after obtaining informed consent and completing the pre assessment form (physical, psychological and socio-economic domains, along with demography, diagnosis and details of treatment received). Program deals with confidence building tips on grooming, Skin and hair care, management of external prosthesis and wigs, lymphedema prevention, Nutritional advice, De-stressing and relaxation techniques Functional exercises for fitness and rehabilitation through supervised fitness and restorative yoga practices. Following the introductory program women are invited to join the 5 day session. The main intervention during this period is supervised yoga, motivation and counseling, meditative practices, guided relaxation, music, dance therapy. The tools used for assessment pre and post intervention are the assessment questionnaire and Hospital Anxiety and Depression (HADS) scale. Many of the physical problems in these women led to emotional problems such as anxiety and depression hence the HADS scale was used.
Results
370 patients were enrolled in the study-86% of patients had breast cancer. Age ranged between 26-76 years. 75% of patients were below 60 years. 18% of the patients below 40 years had breast cancer. The burden of unmet needs was primarily issues related to appearance, hair loss, skin changes, body image, arm swelling, impairment of cognitive factors and emotional problems like depression, anxiety and worry. The percentage of patients with anxiety and depression pre and post interventionTable:
427P
HADS DEPRESSION SCORE | PRE-INTERVENTION | POST-INTERVENTION |
---|---|---|
BORDER LINE (8-10) | 12.50% | 0% |
ABNORMAL (11-21) | 12.50% | 0% |
HADS ANXIETY SCORE | PRE-INTERVENTION | POST-INTERVENTION |
BORDER LINE (8-10) | 18.80% | 0% |
ABNORMAL (11-21) | 37.50% | 0% |
Conclusions
This preliminary study shows that such unique, multidimensional supportive care programs have a significant impact on quality of life through treatment into survivorship phase.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P.P. Bapsy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract